Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Share-based Compensation: 2009-2025

Historic Share-based Compensation for Ani Pharmaceuticals (ANIP) over the last 14 years, with Sep 2025 value amounting to $9.7 million.

  • Ani Pharmaceuticals' Share-based Compensation rose 29.47% to $9.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $35.2 million, marking a year-over-year increase of 26.23%. This contributed to the annual value of $29.3 million for FY2024, which is 42.09% up from last year.
  • As of Q3 2025, Ani Pharmaceuticals' Share-based Compensation stood at $9.7 million, which was up 0.93% from $9.6 million recorded in Q2 2025.
  • Ani Pharmaceuticals' 5-year Share-based Compensation high stood at $9.7 million for Q3 2025, and its period low was $1.9 million during Q1 2021.
  • Its 3-year average for Share-based Compensation is $7.1 million, with a median of $7.1 million in 2024.
  • Its Share-based Compensation has fluctuated over the past 5 years, first plummeted by 50.42% in 2021, then soared by 73.19% in 2022.
  • Ani Pharmaceuticals' Share-based Compensation (Quarterly) stood at $3.0 million in 2021, then grew by 25.91% to $3.7 million in 2022, then skyrocketed by 50.41% to $5.6 million in 2023, then increased by 25.62% to $7.1 million in 2024, then climbed by 29.47% to $9.7 million in 2025.
  • Its last three reported values are $9.7 million in Q3 2025, $9.6 million for Q2 2025, and $8.9 million during Q1 2025.